Abstract 1606P
Background
Sarcopenia refers to the loss of muscle mass and strength that occurs with aging and due to some medical conditions like cancer. Depression and inability to eat without assistance are common effects documented in cancer patients with sarcopenia. As a result, the goal of this study was to look into the relationship between sarcopenia, depression, and modes of feeding.
Methods
During the period beginning in January 2023 and ending in April 2023, cancer patients participated in a retrospective study. There has been a total of 150 participants enrolled in the trial, all of whom have been diagnosed with cancer. These people were enrolled in Mayo Hospital's Palliative Care Cancer Department in order to receive treatment. The Patient Health Questionnaire (PHQ-9) was used to determine the presence of depressive symptoms. The SARC-F was utilized to assess sarcopenia across all five dimensions. A self-report measure was utilized to assess modes of feeding [options include: 1) unable to eat without assistance 2) (self-fed with some difficulty, and 3) self-fed without any problem]. Sarcopenia, major depressive disorder, and feeding modes were studied using correlation analysis.
Results
We have observed a significant and negative association between modes of feeding and depression (r=-0.459, p<0.01), SARC1=Strength (r = -0.326, p<0.01), SARC2=Assistance in walking (r = -0.196, p<0.05), and SARC3=Rise from a chair (r = -0.238, p<0.01). These findings show that cancer patients are unable to eat without assistance when they suffer from sarcopenia which ultimately leads to more depressive symptoms.
Conclusions
Sarcopenia has a negative impact on the quality of life of patients, leading to depression and dependence on daily activities like self-eating which further complicates management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05